Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 16/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | ERG | P11308 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4032505 | 0.89 | CRHR1 (0.43) | CRHR1MMP3MMP12ERGCHRM1 | |
| SCHEMBL4033668 | 0.85 | HDAC1 (0.37) | CRHR1MMP3MMP12HDAC1 | |
| SCHEMBL5848998 | 0.84 | HTT (0.39) | MMP3MMP12HDAC1 | |
| SCHEMBL4036670 | 0.84 | CRHR1 (0.41) | CRHR1MMP3MMP12ERGCHRM1 | |
| SCHEMBL3775689 | 0.83 | CRHR1 (0.58) | CRHR1ERG | |
| SCHEMBL13909016 | 0.82 | CRHR1 (0.48) | CRHR1MMP3MMP12ERGCHRM1 | |
| SCHEMBL5847816 | 0.82 | DRD2 (0.42) | CRHR1MMP3MMP12CHRM1HDAC1 | |
| SCHEMBL4035124 | 0.80 | SPR (0.37) | CRHR1MMP3MMP12 | |
| SCHEMBL4034624 | 0.76 | MMP3 (0.39) | CRHR1MMP3MMP12CHRM1HDAC1 | |
| SCHEMBL5847449 | 0.76 | CRHR1 (0.47) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858809-B2 | Process for production of pyrazole-fused ring derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-28 | — | — | US | disclosed |
| US-7858809-B2 | Process for production of pyrazole-fused ring derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-28 | — | — | US | disclosed |
| EP-1555265-B1 | 7-PHENYL PYRAZOLOPYRIDINE COMPOUNDS | EISAI R&D MAN CO LTD (JP) | 2009-03-25 | — | — | EP | disclosed |
| EP-1555265-B1 | 7-PHENYL PYRAZOLOPYRIDINE COMPOUNDS | EISAI R&D MAN CO LTD (JP) | 2009-03-25 | — | — | EP | disclosed |
| US-20080076943-A1 | 7-PHENYLPYRAZOLOPYRIDINE COMPOUNDS | HIBI SHIGEKI | 2008-03-27 | — | — | US | disclosed |
| US-20080076943-A1 | 7-PHENYLPYRAZOLOPYRIDINE COMPOUNDS | HIBI SHIGEKI | 2008-03-27 | — | — | US | disclosed |
| US-20080076943-A1 | 7-PHENYLPYRAZOLOPYRIDINE COMPOUNDS | HIBI SHIGEKI | 2008-03-27 | — | — | US | disclosed |
| US-7323569-B2 | 7-phenylpyrazolopyridine compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-01-29 | — | — | US | disclosed |
| US-7323569-B2 | 7-phenylpyrazolopyridine compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-01-29 | — | — | US | disclosed |
| US-7323569-B2 | 7-phenylpyrazolopyridine compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-01-29 | — | — | US | disclosed |
| US-20070191613-A1 | Process for production of pyrazole-fused ring derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| US-20070191613-A1 | Process for production of pyrazole-fused ring derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| US-7176216-B2 | 7-phenylpyrazolopyridine compounds | EISAI CO., LTD. (JP) | 2007-02-13 | — | — | US | disclosed |
| US-7176216-B2 | 7-phenylpyrazolopyridine compounds | EISAI CO., LTD. (JP) | 2007-02-13 | — | — | US | disclosed |
| US-7176216-B2 | 7-phenylpyrazolopyridine compounds | EISAI CO., LTD. (JP) | 2007-02-13 | — | — | US | disclosed |
| US-20060235011-A1 | 7-Phenyl pyrazolopyridine compounds | EISAI CO.LTD. (JP) | 2006-10-19 | — | — | US | disclosed |
| EP-1555265-A1 | 7-PHENYL PYRAZOLOPYRIDINE COMPOUNDS | Eisai Co., Ltd. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-20040224974-A1 | 7-phenylpyrazolopyridine compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224974-A1 | 7-phenylpyrazolopyridine compounds | CRHR1, MC2R, CRH | CRHR1 1/4885MMP3 1834/4885MMP12 3639/4885 |
| US-20080076943-A1 | 7-PHENYLPYRAZOLOPYRIDINE COMPOUNDS | MC2R, CRHR1, CRHR2 | CRHR1 2/4885MMP3 1911/4885MMP12 2926/4885 |
| US-20060235011-A1 | 7-Phenyl pyrazolopyridine compounds | MC2R, CRHR1, CRHR2 | CRHR1 2/4885MMP3 2115/4885MMP12 3041/4885 |
| US-20070191613-A1 | Process for production of pyrazole-fused ring derivatives | CYP4F3, CYP4F2, CYP2F1 | CRHR1 2190/4885MMP3 3177/4885MMP12 3370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.